Johnson & Johnson (NYSE:JNJ) Shares Sold by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 79.5% during the 3rd quarter, Holdings Channel reports. The fund owned 1,703 shares of the company’s stock after selling 6,603 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Johnson & Johnson were worth $276,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in JNJ. Prosperity Financial Group Inc. boosted its holdings in Johnson & Johnson by 4.6% in the third quarter. Prosperity Financial Group Inc. now owns 4,418 shares of the company’s stock valued at $716,000 after purchasing an additional 195 shares during the last quarter. Douglass Winthrop Advisors LLC grew its holdings in Johnson & Johnson by 4.5% during the third quarter. Douglass Winthrop Advisors LLC now owns 107,052 shares of the company’s stock worth $17,349,000 after acquiring an additional 4,609 shares during the period. Fisher Asset Management LLC raised its position in Johnson & Johnson by 7.9% during the third quarter. Fisher Asset Management LLC now owns 7,560,199 shares of the company’s stock valued at $1,225,206,000 after acquiring an additional 550,760 shares in the last quarter. Daiwa Securities Group Inc. lifted its holdings in Johnson & Johnson by 8.0% in the third quarter. Daiwa Securities Group Inc. now owns 384,637 shares of the company’s stock valued at $62,335,000 after acquiring an additional 28,628 shares during the period. Finally, Summit Trail Advisors LLC boosted its position in Johnson & Johnson by 15.8% in the 3rd quarter. Summit Trail Advisors LLC now owns 53,162 shares of the company’s stock worth $8,615,000 after purchasing an additional 7,242 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several analyst reports. Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Royal Bank of Canada upped their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.67.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $155.01 on Monday. The company has a fifty day simple moving average of $159.15 and a 200-day simple moving average of $156.46. The firm has a market capitalization of $373.21 billion, a price-to-earnings ratio of 22.43, a PEG ratio of 2.75 and a beta of 0.53. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter in the prior year, the company earned $2.66 EPS. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.